Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, +239

The Lancet

Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment +4

Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Mieke Schutte, Ralph H. Hruban, Joseph Geradts, +10

PubMed

Tumor BiologyPancreatic CancerMedicineP16 GeneCancer Cell Biology +11

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, +247

The Lancet Oncology

Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment +4

Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+.

Michael Goggins, G. J. A. Offerhaus, Werner Hilgers, +7

PubMed

BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in Distinct Subsets of Pancreatic Cancer

Eric S. Calhoun, Jessa Jones, Raheela Ashfaq, +8

American Journal Of Pathology

Tumor BiologyPancreatic CancerSomatic VariantTumor HeterogeneityMedicine +6

Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene.

Gloria H. Su, Werner Hilgers, Manu C. Shekher, +4

PubMed

PathologyP38 MapkCancer BiologyTumor BiologyPancreatic Cancer +15

Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors.

Kenji Okami, Li Wu, Gregory J. Riggins, +11

PubMed

Cancer PathologyPathologyPten/mmac1 AlterationsCancer BiologyTumor Biology +14

Molecular genetic basis of pancreatic adenocarcinoma

Werner Hilgers, Scott E. Kern

Genes Chromosomes and Cancer

Tumor BiologyGenetic TestingOncologyCancer PathologyPancreatic Cancer +12

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

Christian Pfister, Gwénaëlle Gravis, Aude Fléchon, +52

The Lancet Oncology

Survival EndpointsSurgical OncologyUrologyGenitourinary CancerMedicine +5

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Benjamin Besse, Enriqueta Felip, Rosario García Campelo, +88

Annals of Oncology